The company is one of the first in the U.S. with complete end-to-end gene therapy capabilities in Massachusetts, from research and development to therapeutic production at scaleBEDFORD, Mass., June . | June 21, 2023
By Chris Wack Ultragenyx Pharmaceutical said Wednesday that the U.S. Food and Drug Administration has reviewed and agreed to a protocol amendment to a Phase 1/2 study evaluating the safety and. | May 17, 2023
Amended U.S. protocol increases loading and maintenance doses to similar range as ex-U.S. expansion cohortsNOVATO, Calif., May 17, 2023 Ultragenyx Pharmaceutical Inc. today announced that the. | May 17, 2023
NOVATO, Calif., May 05, 2023 Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare. | May 5, 2023